Rotterdam

• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity
• A clinical trial of sacituzumab tirumotecan to treat urothelial cancer (MK-2870-031) Recruiting
  2024-520014-22-00 5 2026-04-22 Locally advanced/metastatic urothelial carcinoma
• Optimization of pain management for acute renal colic in the Emergency Department – The OPTIMIZED trial Recruiting
  2025-521316-19-00 6 2026-04-20 Urolithiasis
• An investigational trial to evaluate the effects of the drug XC001 delivered via a catheter in subjects with chronic angina caused by corona … Recruiting
  2024-514874-36-01 4 2026-04-17 Refractory angina due to obstructive coronary artery disease
• Neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab versus upfront surgery for patients with primary resec … Recruiting
  2024-516898-72-00 10 2026-04-17 Perihilar cholangiocarcinoma, distal cholangiocarcinoma
• PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF E-VIM VACCINE CVX1 WITH OR WITHOUT ICI IN THE TREATMENT OF SUBJECTS … Recruiting
  2025-523781-25-00 1 2026-04-02 metastatic solid cancer, muscle invasive bladder cancer, localized or
• Phase 1 Single Ascending and Multiple Ascending Dose Study with LCA-0321 Recruiting
  2025-524053-14-00 1 2026-04-02 Graves Disease
• The STELLAR trial: Fluorescence-guided surgery in laryngeal- and hypopharyngeal cancer: a feasibility trial Recruiting
  2024-519750-36-00 7 2026-03-31 Squamous cell carcinoma of the larynx and hypopharynx
• A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 Recruiting
  2025-521973-16-00 9 2026-03-31 Netherton Syndrome
• Peri-operative intraperitoneal irinotecan and systemic FLOT in the curative treatment of gastric cancer and gastroesophageal junction cancer … Recruiting
  2025-522864-34-00 3 2026-03-30 Gastric cancer
• Phase 2a Study of Tafasitamab in Adults With Primary Autoimmune Blood Cell Disorders Recruiting
  2025-521286-27-00 10 2026-03-26 Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimm
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting
  2025-522674-36-00 5 2026-03-24 Metabolic Dysfunction-Associated Steatotic Liver Disease
• A study to test whether nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis Recruiting
  2025-522383-33-00 5 2026-03-23 Interstitial lung diseases
• Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin … Recruiting
  2024-518210-81-00 5 2026-03-18 Advanced Hepatocellular Carcinoma
• OCEAN(a)-CCTA - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction -Coronary Computed Tomography Angiography trial Recruiting
  2025-521117-88-00 5 2026-03-11 Cardiovascular Disease
• A study to test the safety and efficacy of the study drug in patients with low blood sugar caused by hormones made by their tumor Recruiting
  2024-515447-36-00 5 2026-03-10 Tumor-associated hyperinsulinism
• The PEARL trial: Prevention of hepatic Encephalopathy by administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoi … Recruiting
  2024-512040-28-01 6 2026-03-01 Confirmed diagnosis of Alcoholic liver cirrhosis
• Effects of ziltivekimab on coronary atherosclerotic burden in patients with acute myocardial infarction Recruiting
  2024-520364-34-00 5 2026-02-23 Acute myocardial infarction
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad … Recruiting
  2025-521124-29-00 10 2026-02-13 Non-Small Cell Lung Cancer
• A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma Recruiting
  2025-522640-41-00 4 2026-02-13 Asthma
• A phase 2, randomized, double-blind study of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease. Recruiting
  2025-522146-40-00 4 2026-02-12 Late-onset Pompe disease.
• INTERACT-FAPI Recruiting
  2024-520037-76-00 3 2026-01-27 Peritoneal metastases
• A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting
  2025-521043-20-00 10 2026-01-27 Neuroendocrine tumors
• Brivekimig for the treatment of moderate to severe hidradenitis suppurativa Recruiting
  2025-522333-61-00 4 2026-01-23 Hidradenitis suppurativa

Showing 169–192 of 818 trials